Get Live Data

SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Graft Polymer PLC Share Price
  4. Graft Polymer PLC Share Regulatory News
  5. Directorate Change

Pin to quick picksGraft Polymer PLC Regulatory News (GPL)

Graft Polymer PLC Information
  • There is currently no data for GPL

Directorate Change

15 Jul 2024 07:00

RNS Number : 2963W
Graft Polymer (UK) PLC
15 July 2024
 

15 July 2024

Graft Polymer (UK) Plc

("Graft Polymer" or the "Company")

 

Director resignation and launch of new corporate website and social media profiles

Graft Polymer (UK) Plc (LON: GPL), an innovative biopolymer drug delivery systems development company, announces the resignation of Mr. Pavel Kobzev from its board of directors with immediate effect. This follows the Company's recent divestiture of its industrial plastics business unit, Graft Polymer D.O.O., announced on 3 May 2024, and the successful completion of its recent fundraise, details of which were announced on 3 July 2024.

Additionally, the Company is pleased to announce the launch of its new corporate website and updated LinkedIn and X (formerly Twitter) profiles. These platforms are designed to reflect the Company's strategic focus on supporting biopharmaceutical companies to enhance the bioavailability, pharmacokinetics, and stability of their therapeutics.

Visit us online:

www.graftpolymer.co.uk

LinkedIn

X (formerly Twitter)

 

Enquiries

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director, Email: anthonytennyson@graftpolymer.co.uk

Yifat Steuer, CFO and Executive Director, Email: yifat@graftpolymer.co.uk

 

Allenby Capital (Broker)

Nick Naylor / Liz Kirchner / James Reeve (Corporate Finance) 

Guy McDougall (Sales) 

+44 (0) 20 3328 5656 

 

About Graft Polymer (UK) Plc

 

Graft Polymer (UK) Plc (LON:GPL) is an innovative developer of biopolymer drug delivery systems dedicated to assisting biopharmaceutical companies in enhancing the effectiveness of their therapeutics. Our proprietary patented platform, a bioabsorbable self-nanoemulsifying drug delivery system (SNEDDS), represents a cutting-edge solution in drug delivery technology. By integrating active pharmaceutical ingredients (APIs) into our novel, patented delivery systems, we enable clients to improve the bioavailability, pharmacokinetics, and stability of their therapeutics.

www.graftpolymer.co.uk | LinkedIn | X (formerly Twitter)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAKZGMNKZRGDZM
12
Date   Source Headline
14th Jan 20257:00 amRNSChange of Name to Solvonis Therapeutics plc
6th Jan 20252:27 pmRNSResult of General Meeting and change of name
16th Dec 20247:00 amRNSProposed acquisition of Awakn Life Sciences Corp
11th Dec 20247:00 amRNSInitial Results University of Nottingham
3rd Dec 20249:44 amRNSNotice of GM and proposed name change
15th Oct 20247:00 amRNSResearch Agreement
4th Oct 20247:00 amRNSResearch and development update
26th Sep 20247:00 amRNSDirectorate Change and grant of options
13th Sep 20247:00 amRNSHalf-year Report
28th Aug 20247:00 amRNSCommercial Collaboration Progress Update
13th Aug 20247:00 amRNSHolding(s) in Company
12th Aug 202410:21 amRNSDirectorate Change
8th Aug 202410:08 amRNSHolding(s) in Company
1st Aug 20247:00 amRNSDirectorate Change
31st Jul 20245:00 pmRNSTotal Voting Rights
23rd Jul 20241:59 pmRNSHolding(s) in Company
23rd Jul 20247:00 amRNSCommercial Collaboration
18th Jul 20247:00 amRNSCommercial Collaboration
17th Jul 20249:28 amRNSHolding(s) in Company
15th Jul 20247:00 amRNSDirectorate Change
12th Jul 20247:00 amRNSHolding(s) in Company
12th Jul 20247:00 amRNSHolding(s) in Company
11th Jul 20249:36 amRNSHolding(s) in Company
11th Jul 20249:27 amRNSHolding(s) in Company
11th Jul 20249:26 amRNSHolding(s) in Company
11th Jul 20249:20 amRNSHolding(s) in Company
11th Jul 20249:20 amRNSHolding(s) in Company
11th Jul 20247:00 amRNSPatent Filings
10th Jul 20244:24 pmRNSHolding(s) in Company
10th Jul 20248:10 amRNSAdmission & Director/PDMR Shareholding
3rd Jul 20242:29 pmRNSPublication of a Prospectus
28th Jun 202412:58 pmRNSResult of AGM
7th Jun 20247:00 amRNSBusiness Update
4th Jun 20244:26 pmRNSNotice of AGM
31st May 20247:00 amRNSPatent Application
28th May 20247:00 amRNSRegulatory Application
9th May 20247:00 amRNSUpdate on recent developments
7th May 20247:00 amRNSGrant of Haemostatic Hydrogel Patent
3rd May 20247:00 amRNSDivestment of Graft Polymer d.o.o – Slo facility
2nd May 20247:00 amRNSReplacement of Chief Executive Officer
30th Apr 20245:05 pmRNSAnnual Financial Report
23rd Apr 20244:17 pmRNSLoan facility update
15th Mar 20247:00 amRNSChairman & Directorate Change & Financial Update
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSGM Statement
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSDirector/PDMR Shareholding
8th Jan 20245:00 pmRNSHolding(s) in Company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
EBQ
Ebiquity
LSE
0.00%
SBID
State Bk.in.gdr
LSE
3.08%
CLDN
Caledonia
LSE
1.57%
TMG
The Mission Group
LSE
0.00%
RTO
Rentokil Initial
LSE
0.84%
Trending
ALRT
Defence Holdings
LSE
4.51%
IMM
Immupharma
LSE
5.42%
HPOW
H-power
LSE
-1.57%
NANO
Nanoco
LSE
18.64%
PPP
Pennpetro Energy
LSE
0.00%